Response to “Interpreting bone turnover responses and treatment persistence with once-weekly teriparatide”

Jiemei Gu, Qi Zhao, Xin Zhang, Zhenlin Zhang · 2026

Read Response to “Interpreting bone turnover responses and treatment persistence with once-weekly teriparatide” by Jiemei Gu, Qi Zhao, Xin Zhang, Zhenlin Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13681506.txt.

Description

Jiemei Gu and co-authors reply to a critical letter about their phase three trial of a once-weekly bone drug, defending their reading of the data point by point. The drug is a biosimilar of weekly teriparatide for osteoporosis. The critics raised four charges: how bone turnover markers were read, whether adherence and persistence were confused, the statistics, and how fracture benefit was framed.

The reply explains why one marker barely moved at week twelve while an earlier study saw a jump at week four, and it supplies background the original report had compressed. Trial methodology is the real subject: what weekly snapshots of bone markers can and cannot say. Bone researchers get a public audit of a trial's soft spots, answered in the open.

Catalog record

CREATORJiemei Gu, Qi Zhao, Xin Zhang, Zhenlin Zhang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13681506

Browse the full library · About the Tower of Babel